Watchlist Price Alert

Alumis Inc. Common Stock (ALMS)

NASDAQ: ALMS · Real-Time Price · USD

5.30

0.79 (17.52%)

At close: May 15, 2025, 3:59 PM

5.35

0.94%

Pre-market: May 16, 2025, 04:02 AM EDT

17.52% (1D)

Bid	5.35
Market Cap	289M
Revenue (ttm)	1.52M
Net Income (ttm)	-294.23M
EPS (ttm)	-10.38
PE Ratio (ttm)	-0.51
Forward PE	-1.32
Analyst	Buy

Ask	5.5
Volume	1,084,323
Avg. Volume (20D)	732,052
Open	4.49
Previous Close	4.51
Day's Range	4.32 - 5.45
52-Week Range	3.18 - 13.53
Beta	-2.17

About ALMS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALMS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALMS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 day ago New

+18.63%

Alumis shares are trading higher after the company... Unlock content with Pro Subscription

1 month ago

+5.82%

Alumis shares are trading higher after the company announced a dermatology collaboration deal with Kaken Pharmaceuticals for ESK-001.

News

1 month ago · businesswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (...

1 month ago · marketbeat.com

3 Biopharmaceutical Stocks Bucking the Sell-Off

With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be look...